论文部分内容阅读
胰腺癌恶性度高,生物学行为特异,目前早期诊断困难,临床疗效不佳。80%的患者就诊时肿瘤已处晚期而无法切除,加之胰腺癌细胞对放化疗有较强的抵抗性,患者病死率达98%。随着肿瘤免疫学的飞速进展,人们逐渐鉴定出了一些胰腺癌相关抗原,并在此基础上进行了免疫学相关的血清标志物检测、分子影像学诊断、肿瘤疫苗、抗体导向免疫治疗等多方面的研究;一些免疫治疗药物和胰腺癌疫苗已进入了临床研究阶段。人们试图通过患者血清中的自身抗体实现对胰腺癌肿瘤抗原的筛查鉴定,从而能更深入地探讨关键分子在胰腺癌生物学行为中的作用,并为其临床免疫诊治提供依据。本文对近年来胰腺癌免疫原性相关抗原的
Pancreatic cancer is highly malignant and has specific biological behaviors. Early diagnosis is difficult and clinical efficacy is poor. 80% of patients treated at the time of the tumor has been advanced and can not be removed, in addition to pancreatic cancer cells have strong resistance to radiotherapy and chemotherapy, the patient mortality rate of 98%. With the rapid progress of tumor immunology, some pancreatic cancer-related antigens have been gradually identified, and on this basis, immunological-related serum markers, molecular imaging diagnosis, tumor vaccines, antibody-directed immunotherapy and many more Research; some immunotherapy drugs and pancreatic cancer vaccine has entered the clinical research phase. Attempts to screen and identify the tumor antigens of pancreatic cancer by autoantibodies in the serum of patients have led to a deeper exploration of the role of key molecules in the biological behavior of pancreatic cancer and provide the basis for their clinical diagnosis and treatment. In this paper, pancreatic cancer immunogenicity related antigen in recent years